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Resumo 
As doenças cardiovasculares são a principal causa de morte nos países desenvolvidos. 
Assim sendo, é importante estudar os mecanismos moleculares causadores destas 
patologias, descobrindo novos mecanismos moleculares subjacentes e factores de risco, 
bem como novas formas de prevenção e terapias mais eficazes.  
 
A desregulação do metabolismo da homocisteína, que leva ao aumento dos seus níveis 
circulantes no plasma (designada por hiperhomocisteinémia), está associada às doenças 
cardiovasculares. No entanto, os mecanismos inerentes à toxicidade vascular da 
homocisteína permanecem ainda por elucidar. Recentemente foi colocada a hipótese de que 
a acumulação do precursor da homocisteína, a S-adenosil-homocisteína (SAH), que ocorre 
em situações de hiperhomocisteinémia, poder conduzir à hipometilação celular, explicando 
assim a toxicidade vascular associada à hiperhomocisteinémia. A SAH funciona como 
inibidor da actividade enzimática da maioria das metiltransferases celulares que usam S-
adenosilmetionina (SAM), o precursor metabólico da SAH, como dador de grupos metilo 
para as reacções de transmetilação que actuam sobre diversos compostos como DNA e 
proteínas, incluindo as histonas. A metilação do DNA e das histonas constituem 
mecanismos epigenéticos que regulam a expressão genética. 
 
A Enhancer of Zeste Homolog 2 (EZH2) estabelece a trimetilação da lisina 27 da histona 
H3 (H3K27me3), uma marca epigenética envolvida na repressão de genes, através do 
aumento da condensação da cromatina. De entre os genes cuja transcrição é reprimida no 
endotélio, incluem-se aqueles que têm um papel na promoção da aterosclerose. A EZH2 é 
uma histona metiltransferase dependente da SAM e, consequentemente, a acumulação de 
SAH poderá afectar negativamente o funcionamento da EZH2. Assim sendo, se os níveis 
intracelulares de SAH aumentarem, o conteúdo de H3K27me3 celular poderá diminuir, com 
a consequente activação de genes pró-aterogénicos, o que contribuirá para o 
estabelecimento da aterosclerose e da patologia cardiovascular. Esta possibilidade constitui 
a hipótese de trabalho investigada no presente trabalho.  
 
Para confirmar esta hipótese avaliámos se a acumulação intracelular de SAH levaria à 
diminuição de H3K27me3, quer in vitro, em células endoteliais humanas, quer in vivo 
usando células mononucleares do sangue periférico obtidas voluntariamente de doentes 
cardiovasculares e de controlos. Os nossos resultados indicam que, in vitro, a acumulação 
intracelular de SAH diminui a marca H3K27me3. Nas células endoteliais, a quantificação dos 
níveis intracelulares de SAM e SAH revelou uma acentuada diminuição da sua razão, 
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confirmando uma capacidade de metilação celular diminuída, quando comparada com 
células controlo. Relativamente aos estudos in vivo, os resultados obtidos demonstraram 
que o conteúdo de H3K27me3 não diferiu de forma significativa nos doentes 
cardiovasculares e a na população controlo, apesar da razão SAM/SAH intracelular estar 
diminuída nos doentes cardiovasculares em relação aos controlos. 
 
 Embora os resultados in vitro corroborem a nossa hipótese, fomos incapazes de 
evidenciar in vivo, um relação inversa entre o ambiente de hipometilação celular e o 
conteúdo da marca epigenética dependente da EZH2 em células mononucleares do sangue 
periférico de doentes cardiovasculares. Assim, serão necessários estudos futuros, numa 
população-alvo mais alargada, para confirmar os resultados obtidos in vivo. Idealmente, 
estes estudos futuros deveriam incidir em doentes cardiovasculares que não estejam 
submetidos a nenhum tipo de medicação. Isto porque os resultados da avaliação de 
mediadores da aterosclerose, como o colesterol por exemplo, foram nitidamente 
influenciados pela terapia a que os doentes cardiovasculares estavam sujeitos aquando da 
colheita de sangue. Por outro lado, estes resultados foram, ainda assim, interessantes, 
comprovando a eficácia da medicação aconselhada aos doentes cardiovasculares, uma vez 
que estes revelaram, no geral, níveis de lípidos circulantes significativamente mais baixos do 
que os indivíduos controlo. 
 
Adicionalmente, investigações futuras deverão alargar o estudo a outro tipo de células, 
como por exemplo células do tecido vascular. Com efeito, o conteúdo da marca epigenética 
H3K27me3 das células estudadas in vivo poderá não representar o conteúdo das células 
endoteliais. Só assim poderemos avaliar inequivocamente se a marca H3K27me3 está 
relacionada com o aparecimento e/ou desenvolvimento de um fenótipo endotelial pró-
aterogénico. Deste modo poderemos também clarificar se a desregulação da actividade da 
EZH2 induzida pela SAH contribui efectivamente para o aparecimento da aterosclerose e 
doença cardiovascular. 
  
Palavras-chave: doença cardiovascular, Enhancer of Zeste Homolog 2, epigenética, 
hipometilação, homocisteína. 
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Abstract 
Cardiovascular diseases (CVD) are the main cause of death in developed countries. Thus, 
it is important to study the mechanism that causes disease progression, uncover new risk 
factors, and new ways of effective prevention and therapeutic approaches. 
Increased levels of circulating homocysteine are associated with cardiovascular disease. 
However, the mechanisms underlying this association remain elusive. Cellular 
hypomethylation caused by accumulations of the homocysteine precursor, S-
adenosylhomocysteine (SAH), may explain homocysteine’s toxicity. SAH inhibits the 
enzymatic activity of most cellular methyltransferases, which use S-adenosylhomocisteine 
(SAM), SAH’s precursor, as a methyl group donor, acting upon several important compounds 
like DNA and proteins, including histones. Methylation of DNA and histones are epigenetic 
mechanisms that regulate gene expression and whose deregulation may cause diseases. 
Enhancer of Zeste Homolog 2 (EZH2) is a histone methyltransferase that establishes 
trimethylation of lysine 27 on histone H3 (H3K27me3), an epigenetic mark associated with 
repression of pro-atherogenic genes in endothelial cells. EZH2 activity depends on SAM, 
therefore SAH accumulation may negatively affect EZH2 methyltransferase activity 
diminishing H3K27me3 content, and leading to the expression these pro-atherogenic genes, 
and to CVD. This possible mechanism constitutes the basis of our work.  
To study this hypothesis, we evaluated whether SAH accumulation leads to H3K27me3 
decrease either in vitro, in human endothelial cells, or in vivo, in peripheral mononuclear 
blood cells (PMBC) of CVD patients. Our in vitro results demonstrate that H3K27me3 content 
decreases if SAH accumulates in the cells. Yet, our in vivo results show no significant 
difference in the H3K27me3 content in PBMC from CVD patients and controls. Although our 
in vitro results corroborate our hypothesis, additional studies with a larger cohort of patients 
and with other cellular material, namely vascular tissue, are necessary in order to ascertain 
whether SAH-induced deregulation of EZH2, and consequent H3K27me3 endothelial 
content, contributes to atherosclerosis and CVD. 
 
Key words: cardiovascular disease, DNA hypomethylation, Enhancer of Zeste Homolog 2, 
epigenetics, homocysteine.    
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I – INTRODUCTION 
 
1. Cardiovascular Disease 
Cardiovascular diseases (CVD) are a group of diseases resulting from dysfunctional 
settings of arteries, veins, and heart1. Within this context, CVD morbidity and mortality are 
usually caused by ischemic heart disease, stroke, and congestive heart failure2, and the 
amount of deaths rises with age3.  
CVD is considered the leading cause of death in developed countries4, causing 17.1 
million deaths every year5, and this number is expected to grow up to 23.6 million by the year 
of 20306. In Portugal, the percentage of deaths attributed to CVD by gender is higher in 
women than in men, as illustrated in Figure 1, where the percentage of death due CVD in 
2013 is shown. 
Results worldwide correspond to CVD death percentage in relation to total deaths at a national level. The color 
bar scheme indicates the percentage of CVD death rate, from the lowest, represented in dark blue, to the highest, 
represented in red. Results of Portugal correspond to CVD death percentage in relation to total deaths per 
gender.  
Abbreviation: CVD, cardiovascular disease. 
Data source collected from references
7,8
. 
 
In approximately ten per cent of cases CVD are an heritable condition9, but there are 
numerous non-heritable risk factors contributing to CVD, such as hypertension, smoking, 
diabetes, bacterial infections, inappropriate vitamin consumption, abnormal blood 
cholesterol, high blood pressure, lack of exercise, obesity or overweight, aging, and high 
plasma levels of homocysteine (Hcy)1,6,10–15. Air pollution has also shown to increase the risk 
for CVD morbidity and mortality, even though it depends on the individuals’ ethnicity16.  
Figure 1. Percentage of deaths due to CVD in relation to total deaths in 2013. 
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CVD develops after a prolonged asymptomatic phase17 and negative cardiovascular 
events may occur in the absence of notorious risk factors18, therefore, it is important to find 
new ways to diagnose and prevent these group of diseases.  
The cardiovascular systems is composed by the heart, connected to a network of arteries, 
veins, and capillaries19. Different cell types constitute the vessel wall, such as smooth muscle 
cells, and endothelial cells (EC)20. The endothelium is composed by a monolayer of EC, 
coating the entire vascular system21. In normal conditions, the endothelium is in a quiescent 
state, with a turnover rate from months to years. It conducts the blood ensuring the nutritional 
support for organs, and regulates vascular tone, platelet activity, and blood vessel formation 
and growth. The endothelium also plays a role on innate and adaptive immunity, by 
regulating leukocyte adhesion and hemostasis22–25. It also limits clot formation, by 
maintaining blood’s fluidity, and functions as a barrier between blood and surrounding 
tissues24.  
1.1. Endothelium dysfunction, atherosclerosis, and CVD 
The homeostasis of the endothelium may be disturbed by metabolites, hormones23 and by 
microbiological, immunological or mechanical insults, resulting in vascular injury26. Upon 
injury, the endothelium will undertake major changes27, causing the reshaping of the vessel 
wall, both in size and composition28. In this process, the endothelial barrier permeability is 
disrupted29, leading to arterial stiffness, and to endothelium dysfunction (ED)19. ED is 
characterized by vasoconstriction, vascular inflammation, upregulation of cytokines and 
adhesion molecules, and decreased bioavailability of nitric oxide (NO)30,31. NO is an 
important molecule with vasodilatory properties and cardioprotective effects31. The reduction 
of NO bioavailability occurs due to NO synthase disruption32, as NO is synthesized from ʟ-
arginine via endothelial NO synthase (eNOS), which has anti-atherogenic functions33. ED is 
linked with eNOS dysfunction34. 
ED is the initial stage of atherosclerosis, which is the leading cause of CVD24,35. 
Atherosclerosis is a multifactorial disease that progresses with age, usually begins in youth 
and continues asymptomatic until a later point in life36,37. It develops in the intima of middle 
and large size arteries, mainly in vessel bifurcations38 and inner curvatures39, mostly in areas 
of disturbed blood flow40. Alterations like vascular remodeling, calcification, oxidative stress, 
cell death, and in lipoprotein metabolism occur during atherosclerosis development36. Ages 
over 45 years for men and 55 years for women are a risk factor41. Aged vessels are more 
susceptible to develop vascular injuries and impaired angiogenesis, therefore they can easily 
develop atherosclerosis19. Until today, there is no way to reverse atherosclerosis by medical 
therapeutics42. 
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 The accumulation of low-density lipoprotein (LDL) in the subendothelial matrix is an initial 
step of atherosclerosis43. LDL can diffuse passively through EC junctions, and its interaction 
with apoliprotein B (apoB) seems to be important for its retention in the vessel wall43, and 
consequent progression of atherosclerosis. ApoB is the principal apolipoprotein of LDL and 
the largest isoform present in the body35, allowing the internalization of LDL particles by the 
cells, so they can absorb cholesterol44. LDL and other apoB-containing lipoproteins can 
accumulate in the intima43. LDL can undertake modifications like oxidization. Oxidized LDL 
(ox-LDL) can activate EC, monocytes and macrophages38. 
 
Figure 2. Schematic representation of the atherosclerotic process. 
The structure of a normal artery is represented with the endothelial cell layer at the top, followed by the intima 
(exaggerated in this figure), and smooth muscle cells at the bottom. Changes in the blood flow affect EC, 
influencing their permeability and gene expression, leading to a decreased NO bioavailability. The retention of 
LDL and other lipoproteins are a key initiator event. LDL undergoes oxidative modification, which are, inhibited by 
HDL. Oxidized LDL stimulates the production of adhesion molecules (like ICAM-1 and VCAM-1) by EC, resulting 
in PBMC recruitment into the vessel wall. Oxidized LDL forms aggregates that are recognized by macrophages 
(derived from monocytes), that forms foam cells. When they die, foam cells contribute to a growing mass of debris 
and lipids that accumulate over time. 
Abbreviations: LDL, low-density lipoprotein, NO, nitric oxide; ICAM-1, intercellular adhesion molecule-1; VCAM-1, 
vascular cell adhesion molecule-1; PBMC, peripheral blood mononuclear cells; Ch, cholesterol; HDL, high-density 
lipoprotein; EC, endothelial cells. 
Adapted from references
43,45
. 
 
The upregulation of adhesion molecules, such as vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), will favor the adhesion of 
peripheral blood mononuclear cells (PMBC - namely lymphocyte and monocytes) to the 
endothelium31, as shown in Figure 2. Moreover, the dysfunctional EC phenotype will increase 
the expression of pro-inflammatory cytokines, promoting the entrance and retention of 
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cholesterol containing LDL in the artery wall and modifications of LDL structure can increase 
the expression of adhesion molecules in EC46–48. LDL is composed by phospholipids and free 
cholesterol, and acts as a cholesterol transporter44.  
These accumulations can occur over time42, as lipoprotein retention seems to be a self-
perpetuating process35, maintained by the dysfunctional EC phenotype46. This process 
results in EC activation, and acts as a chemoattractant for monocytes38, and can also be an 
indicator of oxidative stress18. 
Atherosclerosis is characterized by high plasma concentrations of cholesterol49, that leads 
to the formation and growth of the atherosclerotic plaque41. These plaques are formed by 
accumulation of fibrous materials, cell debris, minerals, and lipids50; infiltration of immune 
cells leads to the establishment of a collagen fibrous cap45. Proliferation and migration of 
vascular smooth muscle cells (VSMC) can occur, as well as accumulation of collagen and 
proteoglycans, resulting in blood vessel obstruction28.  
 
In opposition to LDL, high-density lipoprotein (HDL) has a protective function against 
atherosclerosis. HDL is responsible for the cholesterol efflux from macrophages, through the 
action of apolipoprotein A-I (apoA-I), transporting the cholesterol back to the liver51. From 
there, HDL go to the intestine where apoA-I is liberated from lipids, so it can be attached to 
new HDL particles, or it is degraded in the kidneys52. HDL may have a protective role upon 
ED, by enhancing NO release, preventing apoptosis, and reducing oxidative damage29,51. 
Nevertheless, HDL seems to function as a chameleon-like lipoprotein, having anti-
inflammatory functions in the absence of an acute phase response or systemic inflammation, 
and promoting inflammation in the reverse case scenario53.  
With the progression of atherosclerosis, deposits of C-reactive protein (CRP), an innate 
immune response protein, can also be found in the intima54,55. CRP may affect the 
expression of endothelial cell adhesion molecules, chemokine production and contributes for 
EC’s apoptosis21. CRP levels may depend on the individuals genetic variation56.  
Besides CRP, fibrinogen is also associated with atherosclerosis development15. High 
levels of plasma fibrinogen are found in patients with acute thrombosis, and acute coronary 
syndrome57. Fibrinogen is a complex hexamer composed by α, β and γ chains58, and it is the 
major plasma coagulation factor59. The isoform γ’ is associated with atherothrombotic 
events60. 
 
As the plaques grow, EC proliferate43 and plaques can extend beyond into the arterial 
lumen61, being able to form a necrotic core45. The lesions will grow continuously until a critical 
point, leading to the narrowing of the lumen (stenosis). At some point, the dilation of the 
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artery can no longer compensate stenosis49, macrophages will become apoptotic42 and will 
destabilize the atherosclerotic plaque62. The plaques can grow enough to block the blood 
flow, leading to vein occlusion and eventually resulting in adverse vascular events as 
myocardial infarction (MI) or stroke43. Alternatively, the degradation of the fibrous cap may 
lead to plaque rupture43,63, releasing prothrombotic factors, promoting thrombosis38,41. The 
beginning and development of CVD complications depend on the interplay between 
inflammation response and oxidative stress64. If the inflammatory response continues, the 
artery wall will thicken and harden41, and the number of macrophages and lymphocytes will 
increase, leading to the release of cytokines, chemokines, growth factors, and hydrolytic 
enzymes. Over time, this could lead to focal necrosis49.  
Elevated shear stress can lead to platelet aggregation and further plaque rupture. On the 
other hand, a low shear stress permits the formation and development of atherosclerotic 
plaques10. Activated EC will also interact with leukocyte through the same adhesion 
molecules and through pro-inflammatory cytokines, like IL-6 and -829. Monocytes produce IL-
1β, a powerful cytokine, and high levels of IL-1β seems to contribute for atherosclerosis 
development65.  
2. Homocysteine Metabolism 
Homocysteine (Hcy) is formed during the metabolism of methionine (Met)66, an essential 
amino acid found in foods with high protein content1.  
Met is transformed in S-adenosylmethionine (SAM), a reaction catalyzed by methionine 
adenosyltransferase (MAT, EC 2.5.1.6), which has two isoenzymes: one distributed along all 
tissues and another present in the liver67. SAM is the universal methyl donor in the cell, and 
specific methyltransferases transfer SAM’s methyl group to various molecules like DNA, 
RNA, proteins or lipids68,69. After the transfer of the methyl group, S-adenosylhomocysteine 
(SAH) is formed. SAH is a strong competitive inhibitor of the catalytic action of most SAM-
dependent methyltransferases67,70. As such, high levels of SAH may decrease the cellular 
methylation status71. SAM/SAH ratio is used as an indicator of cellular methylation potential, 
and decreased SAM/SAH values indicate that the cell is hypomethylated72.  
SAH is further hydrolyzed into Hcy and adenosine by SAH hydrolase (SAHH, EC 3.2.2.9) 
through a reversible reaction that favors SAH synthesis. However, in physiological 
conditions, Hcy is quickly metabolized, favoring SAH hydrolysis66,67,72.  
 
Following its production, Hcy can be catabolized by the transsulphuration pathway, in 
which Hcy and serine are condensed into cystathionine, by the action of cystationine-β-
synthase (CBS, EC 4.2.1.22), that uses pyridoxal phosphate (PLP), the active form of vitamin 
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B6, as co-factor
67. Cystathionine is converted into cysteine which will be further oxidized into 
urinary sulphates that are eliminated from the body73, as illustrated in Figure 3. Interestingly, 
the transsulphuration pathway is absent in vascular and myocardial cells due to the lack of 
CBS, and for this reason the cardiovascular system is highly susceptible to Hcy 
accumulations and resulting toxicity32. 
Figure 3: Homocysteine metabolic pathway.  
Abbreviations: Met, methionine: MAT, ATP-ι-methionine S-adenosyltranferase; SAM, S-adenosylmethionine; 
SAH, S-adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; Hcy, homocysteine; THF, 
tetrahydrofolate; MS, methionine synthase; BHMT, betaine-homocysteine methyltransferase; MTHFR, 5,10-
methylenetetrahydrofolate reductase; SHMT, serine hydroxymethyltransferase; CBS, cystathionine β-synthase; 
PLP, pyridoxal phosphate; Vit, vitamin. 
Adapted from reference
67
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Met consumption only provides a portion of the body’s needs and its synthesis requires a 
lot of energy; so, the organism depends on optimal Hcy recycling1. Hcy can be remethylated 
into Met through two ways: a folate-dependent pathway or a folate-independent pathway68. In 
the folate-dependent pathway, methionine synthase (MS, EC 1.16.1.8) is responsible for the 
conversion of Hcy into Met74. 5-Methyl tetrahydrofolate (5-methylTHF) supplies the methyl 
group used by MS for Hcy remethylation66. MS requires vitamin B12 as a co-factor and 
produces also tetrahydrofolate (THF)75. THF is further reduced of 5,10-
methylenetetrahydrofolate (5,10-methyleneTHF), and then converted into 5-methylTHF, by 
the action of methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.20)75. Mutated MTHFR 
can lead to Hcy accumulation76.  
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The betaine-homocysteine pathway is a folate-independent remethylation cycle, in which 
Met is produced from Hcy by a reaction catalyzed by betaine-homocysteine 
methyltransferase (BHMT, EC 2.1.1.5) that uses betaine as a methyl donor group. Betaine is 
then converted into dimethylglycine67,68. 
 
Adequate levels of B vitamins are mandatory to ensure a regular metabolism of Hcy77. 
Accordingly, deficiencies in B vitamins can lead to an increase Hcy circulating levels74. On 
the other hand, treatments with folic acid can lower the levels of accumulated Hcy78. 
Women tend to have lower Hcy circulating levels than men, probably due to the influence 
of sex hormones1. Also, Hcy levels increase progressively with age79.  
2.1. Homocysteine and link to disease 
High Hcy plasma levels are associated with atherosclerosis69, and Hcy is considered to be 
an independent cardiovascular risk factor70. Meta-analyses have shown that increases of 3 - 
5 μmol/L of Hcy in the plasma can enhance 10 % - 27 % the risk for thromboembolism, 
myocardial infarction, or stroke80. 
The increase of plasma Hcy levels (hyperhomocysteinemia or HHcy) have been linked to 
impaired endothelial vasodilation81, platelets aggregation, vascular inflammation32, and ED82. 
A large cohort study, performed in Italy, demonstrated that high plasma levels of Hcy were 
linked to coronary atherosclerosis32. Subjects presenting HHcy also exhibited high levels of 
circulating SAH in the plasma and alterations in DNA methylation pattern in the 
lymphocytes67. 
Several mechanisms have been proposed to explain the vascular toxicity of Hcy. Various 
studies showed that increased levels of plasma Hcy are important for the initiation and 
progression of vascular disease, including ED, inhibition of methylation due to SAH 
accumulation, protein modification at a post-translational level, decreased NO levels, and 
increased oxidant stress83.  
The beneficial effects of folate supplementation as an Hcy-lowering therapy aiming to 
diminish CVD risk are still controversial. Oral administration of folic acid, either alone or in 
combination with vitamin B12 has shown to lower Hcy levels
84, and folic acid supplementation 
in HHcy subjects can ameliorate endothelial-dependent dilatation32. Also, vitamin B ingestion 
may lead to carotid plaque decay, even in patients with normal Hcy levels85. Other studies 
also confirmed the benefits of folate. For example, a Canadian cohort study revealed that low 
folate levels in the serum were linked to a higher coronary heart disease. Also, the US 
Physician Health Study showed that low folate levels were linked to a higher probability of 
acute myocardial infarction86. 
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However, the NORVIT trial showed that treatments with folic acid and with vitamin B6, 
although effective in diminishing plasma Hcy levels, did not lowered CVD risk78. Other 
studies also confirmed these negative results. For example, the SEARCH study, a large Hcy-
lowering trial could not show the advantage of vitamin B consumption on reducing the CVD 
risk84. Another example is the VISP study, which did not show benefits of high-dose vitamin 
therapy on the outcome of stroke, coronary heart disease or death85. 
These controversial studies lead to an impasse in the scientific field of Hcy research. In 
fact, several authors claimed that it would be expected that treatments aiming to lower Hcy 
levels should reduce the associated cardiovascular risk47. Nonetheless, current views hold 
that several factors may explain these contradictory results. For example, most studies had a 
less than 5 years period of follow-up, an insufficient period of time to allow accurate 
conclusions about CVD risk decline, when atherosclerosis is a chronic condition that takes 
years to develop87. Importantly, SAH, and not Hcy, is now considered the main culprit for 
vascular toxicity associated to HHcy. In accordance, a study revealed that vitamin B 
supplementation, which can reduce Hcy plasma levels, did not decreased SAH levels82. 
2.2. Homocysteine and cell hypomethylation  
Currently SAH, the Hcy precursor, which accumulates in the setting of HHcy, is considered 
a more accurate measure of CVD risk than Hcy82,88. As discussed before, under normal 
conditions, the reaction catalyzed by SAHH favors Hcy rather than SAH synthesis67. 
Nevertheless, if Hcy accumulates (due to genetic or nutritional causes), SAH will increase as 
well82. As referred above, SAH inhibits almost all SAM-dependent methyltransferases70. In 
fact, this inhibitory effect of excess SAH may explain the vascular toxicity attributed to HHcy. 
Thus, excess SAH may promote hypomethylation of DNA, proteins, and other small 
molecules. Several observations support this possibility. For example, in cultured cells, 
elevated SAH levels leads to gene-specific DNA hypomethylation80. Additionally, increased 
levels of SAH (and low SAM/SAH ratios) were observed in plasma and in erythrocytes from 
HHcy subjects with occlusive vascular disease74. Furthermore, the Met&Gen Group have 
demonstrated that intracellular accumulation of SAH results in DNA and protein 
hypomethylation. Moreover, a SAH-induced hypomethylating environment promotes ED and 
a pro-atherogenic phenotype of EC89.  
 
The methylation status of DNA and histone-proteins constitute epigenetic marks that 
modulate gene expression. As such, these observations support the hypothesis that SAH-
induced epigenetic deregulation may underlie HHcy-related CVD. 
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3. Epigenetics  
Epigenetic changes are heritable changes in gene expression that do not involve any 
alteration in the underlying DNA sequence90 and that may be mediated through complex 
genome-environment interactions91. The environment can induce stable modification in the 
cell function that persist until adulthood, leading to a panoply of phenotypes, including 
disease risk92. Epigenetic changes affect gene function by altering the packing of chromatin 
(chromosomal DNA associated with histone proteins) and, consequently, the genome 
stability and the accessibility of regulatory proteins69,71,93. Epigenetic changes can also result 
in inappropriate gene silencing or expression17,94.  
Numerous types of human diseases, including CVD, have been linked to epigenetic 
alterations28. Environmental factors, like diet, can trigger epigenetic modifications associated 
with CVD, as exemplified by the Dutch Hunger Winter case, where it was observed that food 
restriction during pregnancy had long-lasting consequences for adult health, including 
increased risk for coronary heart disease69. Besides diet, other habits like smoking, exercise, 
and endocrine exposures may lead to transgenerational nongenomic modifications92.  
There are various types of epigenetic modifications and these include histone and DNA 
modifications95, which are linked to Hcy metabolism.  
3.1. DNA methylation 
DNA methylation has an important role in various biological processes including 
development, inactivation of the X chromosome in females, imprinting, and suppression of 
DNA sequences that are considered as parasitic96. Methylation in repetitive gene sequences, 
like satellite DNA, are a necessary step for normal gene regulation, as it enables spatial 
positioning of the chromosomes97. DNA methylation is a powerful way to silence gene 
expression93 and can also influence transcriptional elongation process, alternative splicing98, 
and cellular growth, differentiation, survival and senescence99.  
In mammalian genomes, methylation deposition normally occurs in 5’ cytosine (C) that 
precedes guanine (G), or CpG dinucleotides. High density of CpG dinucleotides form the so-
called CpG islands100, the majority located in gene promoters, including housekeeping 
genes, tissue-specific genes and developmental regulatory genes96. DNA methylation 
generally leads to increased chromatin condensation and inhibition of normal DNA-protein 
binding, which leads to gene silencing97,100.  
DNA methyltransferases (DNMT) are SAM-dependent enzymes that establish and 
maintain DNA methylation patterns. Mammals possess different types of DNMT: DNMT1, 
and DNMT3A and DNTM3B. DNMT1 functions at a post DNA-replication level, maintaining 
the methylation pattern100 as it copies the methylation pattern during mitosis92, although it can 
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also have de novo methylation capacities40. DNMT1 activity seems to be lower in EC 
exposed to Hcy71, and in advanced stages of atherosclerosis, DNMT1 expression decreases 
significantly, causing a global reduction of DNA methylation101. Also, DNMT1 expression can 
be induced by disturbed blood flow102. 
DNMT3A and DNMT3B are associated with de novo methylation processes93,100 which can 
occur in 3 - 5 % of adult somatic cells during mitosis17. In peripheral blood mononuclear cells 
(PBMC), low DNMT3A/B levels are associated with high SAH levels. Nevertheless, this 
relation between increased Hcy levels and decreased DNMT-mediated hypomethylation is 
not widely accepted103.  
It has been observed that in vivo inhibition of DNMT led to low levels of atherosclerotic 
plaque development102. In fact, alterations in the DNA methylation capacity leading to 
hypomethylation have been reported in CpG islands of patients with heart failure69. Also, 
DNA methylation was found to play an important role in atherosclerosis development72, as 
DNA hypomethylation was reported in VSMC of advanced atherosclerotic plaques in human 
patients17. Also, DNMT expression seems to respond to disturbed blood flow, which in turn, 
regulates endothelial gene expression and function, which could lead to atherosclerosis46. 
Experiments with animals models demonstrated that DNA methylation has great 
implications in the development of atherosclerosis, as mice without DNMT genes showed 
DNA hypomethylation in their lymphocytes and an increase in inflammatory mediators17.  
 
DNA methylation patterns can be modified by various factors: nutrition, chromatin 
accessibility, HHcy state, oxidative stress, inflammation, aging, or SAM and SAH 
availability93. SAH has the ability to bind to DNMT with more affinity than SAM does, thus 
inhibiting their activity and subsequent DNA methylation reactions. This explains why 
patients with HHcy can show alterations in DNA methylation pattern of their PBMC72. 
Alteration of the DNA methylation pattern induced by SAH results in hypomethylation and 
enhances DNA’s sensitivity to SAH toxicity82.  
Furthermore, hyper-mutability of distinct cardiac genes can be attributed to disturbed DNA 
methylation patterns104. Atherosclerotic patients showed DNA strands breaks and 
chromosomal damage in VSMCs and other circulating cells105. In coronary arteries of 
patients with advance atherosclerotic plaques, hypomethylation of genes involved in 
inflammation and immune responses was reported106. 
 
New sequencing chemistries have the advantage to reveal direct DNA methylation 
measures107. Recently, the epigenome-wide survey of human candidate genes that partake 
in atherogenesis revealed, in atherosclerosis patients, a genome-wide increase in DNA 
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methylation levels, contrary to expectations108,109. Large genome sequencing studies also 
reported an increase of global DNA methylation levels as atherosclerosis evolves9. Although, 
genome-wide and age-related studies showed that DNA hypomethylation was predominant9. 
Differences in the methylation pattern in different studies can be explained by the response 
of different cell types upon atherogenesis106. 
 
Lastly, DNA methylation can enable histone modifications but on the other hand, histone 
methylation can facilitate DNA methylation101, as methylated intragenic regions have a strong 
effect on histone modifications98. Histone modification can act as docking sites, recruiting 
chromatin-modifying enzymes, regulating specific transcriptional gene’s states110. 
3.2. Histone methylation 
Histones are nuclear proteins that form globular octamers of H2A, H2B, H3 and H4 
assemblies, around which 146 base pairs of DNA segments are wrapped. These assemblies 
form the nucleosomes, which are the basic units of chromatin111–113. Nucleosome structure 
changes according to histone charges, which affect the chromatin structure by interfering 
with the contact between histones and DNA and between different histones114,115. 
Nucleosome disposition can block the access of transcription factors and polymerases111, 
thereby blocking gene transcription93,116.  
Changes of histone charges usually occur in amino acid residues present in their tails117. 
Histones are susceptible to different modifications, including methylation115. 
The effects of histone methylation on transcription depend on the specific residues that are 
methylated. For example, methylation of lysines 4, 36 and 79 in histone H3 are mainly 
associated with active transcription110, while methylation at lysines 9 and 27 are associated 
with gene repression. Furthermore, the methylation status of a single lysine residue can be 
determinant for gene expression112. In fact, lysines can be mono-, di-, or trimethylated115, 
these marks are associated with both active and inactive chromatin, depending on the 
methylation degree and the position within the nucleosome and gene112. Trimethylated 
histone H3 lysine 4 (H3K4me3) is a mark of active promoters110, while di- and trimethylated 
histone H3 lysine 9 (H3K9me2/3) residues are strongly associated with transcriptional 
repression118. 
Additionally, one of the most studied histone modifications is the epigenetic mark 
H3K27me3 (trimethylation of histone H3 at lysine 27), known for heritable gene silencing 
expression110,114. DNA hypomethylation and global alterations in histone tail can lead to an 
increase of H3K27me3 levels119.  
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Histone methyltransferases (HMT) are enzymes with the ability to methylate histones and 
depend on SAM as the methyl donor compound. Although there are other HMT100, we will 
focus on the one responsible for the catalytic activity towards lysine residues112: the 
Enhancer of Zeste Homolog 2 (EZH2). 
3.2.1 Enhancer of Zeste Homolog 2 
Polycomb group proteins (PcG) are widely expressed120 and represent an evolutionary 
conserved multiprotein family that include the polycomb repressor complex 2 (PCR2)121. PcG 
are epigenetic regulators of transcription, leading to repression of gene expression97. EZH2 
is a SET-domain (Su(var)3-9; E(z); Trithorax)122,123 HMT, that represents the catalytic core of 
PCR299,124, which epigenetically silences gene expression125. Also, EZH2 relies on SAM as a 
methyl-donor compound99. EZH2 can associate with DNMT as they both might function with 
a similar mechanism for silencing gene expression. The interaction between EZH2 and 
DNMT seems to facilitate the binding to promoters of genes that are targets of EZH2126. 
PCR2 is known to respond to high nucleosome density, leading to a higher level of 
chromatin condensation, and therefore, gene repression127. In fact, H3K27me3 in repressed 
genes will recruit PCR2 to copy the methylation pattern, during DNA replication. This way, 
the methylation pattern will be conserved in both DNA strands even after cell division, 
assuring the cell’s identity as it controls the gene expression profile121.  
 
H3K27me3-enriched repressive chromatin structure is crucial for stem cells to maintain 
their quiescent and undifferentiated status128–130. In a wide variety of cancer cells EZH2 is 
overexpressed97,131. In contrast to studies in cancer cells, little is known concerning EZH2 
role in differentiated cells. Recent studies revealed that EZH2 epigenetically regulates EC 
proliferation, migration, and communication, and angiogenesis125,132. Additionally, EZH2 
target genes consist of several mediators implicated in ED, including pro-inflammatory 
cytokines that induce endothelial cell expression of adhesion molecules125. The same 
phenotype that Met&Gen Group reports had attributed to excess SAH89. As such, these 
observations raise the possibility that deregulation of epigenetic control mediated by EZH2 
may contribute to ED and CVD125. In support, a reduction in global histone H3K27me3 in 
atherosclerotic plaques was just reported133.  
 
In addition, the Met&Gen Group recently reported that, in cultured human endothelial cells, 
SAH decreases EZH2 expression and reduces the content of the epigenetic mark 
H3K27me3. Furthermore, EZH2 knockdown recapitulated the effects of excess SAH on 
endothelial activation, i.e., it induced up-regulation of adhesion molecules and cytokines. 
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These findings suggest that suppression of EZH2 activity by excess SAH may contribute to 
the vascular toxicity of HHcy89. This constitutes our working hypothesis that is illustrated in 
Figure 4. 
 
Figure 4: Potential mechanism(s) by which SAH causes endothelial activation.  
SAH can inhibit EZH2 activity leading to a decrease in repressive histone mark H3K27me3, which suppresses the 
expression of various genes, including IL-1β. Exposure to excess of SAH activates the transcription of cytokines 
(such as IL-1β) and adhesion molecules (such as ICAM-1 and VCAM-1), contributing to endothelial cell activation, 
which leads to endothelial dysfunction. 
Abbreviations: SAH, S-adenosylhomocysteine; EZH2, Enhancer of zeste homolog 2, H3K27me3, trimethylation of 
lysine 27 in histone H3; IL-1β, interleukin 1-β; VCAM-1, vascular adhesion molecule-1; ICAM-1, intercellular 
adhesion molecule-1.  
Adapted from reference
89
. 
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II - OBJECTIVES 
 
We postulate that hypomethylating stress induced by high levels of SAH will suppress 
histone H3 specific methylation, therefore contributing to a pro-atherogenic endothelial 
phenotype. We believe that a decreased content of the repressive epigenetic mark 
H3K27me3 induced by excess SAH will promote atherogenesis and CVD. Recently, 
Loscalzo and colleagues134 validated the use of peripheral blood cells in the study of the 
pathophysiology of atherosclerosis-related diseases. Thus, and considering our working 
hypothesis, the objectives of this work are:  
 to confirm, in vitro, the ability of SAH to decrease the H3K27me3 mark 
 to determine the content of H3K27me3 mark in PMBC of healthy individuals and CVD 
patients 
 to evaluate whether H3K27me3 mark is associated with plasma and PMBC markers 
of hypomethylation and atherosclerosis, and whether they correlate with CVD 
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III – METHODS AND MATERIALS 
A. In vitro studies: incubation procedure in endothelial cells 
Human umbilical endothelium cells (HUVEC)135 are a cellular model widely used to study 
the atherosclerosis process136, since their phenotypic changes are similar to those of the 
adult vascular endothelium137. To test the ability of SAH to diminish the endothelial 
H3K27me3 epigenetic content we performed in vitro studies in HUVEC. 
A.1. Cell culture and treatments 
HUVEC from pooled donors (Lonza) in passage 2 were cultured in T75 flasks with filter cap 
(Orange Scientific, Belgium), at 37 °C with 5 % CO2, in a Hera Cell 150 incubator (Thermo 
Scientific by Thermo Fisher Scientic, Waltham, MA, USA). Cells were grown in EGM™-2 
Medium containing SingleQuot™ Kit supplements, including antibiotic and antimitotic (Lonza) 
until 70 - 80 % confluency and were further harvested with a 1:3 split. In this process, the 
medium was removed, cells were washed twice with DPBS (Lonza) without calcium and 
magnesium, and 0.5 % trypsin – EDTA (Gibco™ by ThermoFisher Scientific, Waltham, MA, 
USA) diluted in DPBS (1:10) was added. After 2 min at 37 oC, the cells were collected and 
grown in fresh culture medium at 37 oC, which was replaced 12 h after tripsinization, and 
further, every 48 h. 
Both DPBS and EGM™-2 Medium were filtered before usage, with the help of a stericup® 
and steritop™ vacuum-driven filtration TM PLUS system with 0.22 μm connected to a 
chemical duty pump, 220 V/50 Hz WP6122050 pore (Merck Millipore, Darmstadt, Germany).  
 
Experiments were performed between passages five and eight and with cells 70 to 80 % 
confluent. Adenosine-2,3-dialdehyde (ADA), a SAHH inhibitor, was used to increase the 
intracellular levels of SAH135. Treatments with ADA were performed for 24 or 48 h at 20 μM. 
A sterile solution of ADA was used, which was obtained using a 5 mL Terumo® sterile 
syringe (Terumo Corporation, Japan) and a sterile syringe-driven 0.22 μm filter (Millex® from 
Merck Millipore, Darmstadt, Germany). Cells incubated in unsupplemented medium were 
used as control. 
All cell manipulations were executed in a Holten Laminar flow hood HVR 2640 (Thermo 
Scientific). 
A.2. Sample preparation 
After the incubation period, the culture medium was removed and the cells were washed 
twice with DPBS (Gibco™ by ThermoFisher Scientific). Cell detachment was executed in 
500 μL of DPBS using a 23 cm cell scrapper (Orange Scientific, Belgium); a process 
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repeated two more times. All manipulations were performed on ice, outside the flow 
chamber. The cells were collected into a 2 mL sterile microtube (Eppendorf, Hamburg, 
Germany) and centrifuged at 4000 rpm for 2 min in a Hermle Z233M-2 centrifuge (Labnet 
International, Inc, Edison, USA). Part of the pelleted cells was immediately deproteinized by 
adding 100 μL of 10 % perchloric acid (v/v) and stored at -80 oC in an ultra-low temperature 
freezer (Panasonic Biomedical Sales, Japan) until SAH and SAM analysis. The remaining 
cells were also stored at -80 oC until further Western blot analysis. 
A.3. SAM and SAH analysis 
Deproteinized cell extracts were sent to the Metabool Laboratory at VU Medisch Centrum, 
in Amsterdam, The Netherlands, to measure SAM and SAH content by tandem mass 
spectrometry, as previously described138. 
A.4. Western blot analysis 
A.4.1. Histone extraction 
Histone can be extracted following nuclei isolation139. With this purpose, the cells were 
lysed by hypotonic lysis buffer (HLB: 10 mM Tris-HCl pH 8.8; 1 mM KCl; 1.5 mM MgCl2; 1 
mM diothiothreitol; 25x complete protease inhibitor; in diethylpyrocarbonate (DEPC) treated 
water) followed by 30 min incubation on ice in a Rocker 25 agitator (Labnet International, 
Inc). Protein extraction is usually executed at 4 oC, as they can easily denaturate once 
released from cells140.  
After the incubation with HLB, the microtubes containing the cell lysates were centrifuge at 
10000 g for 10 min at 4 oC. To the obtained pellets, 50 μL of 0.25 M H2SO4 were added and 
lefted incubating on ice in a Rocker 25 agitator for at least 2 h. At this point, most of nuclear 
proteins had precipitated139. Then 200 μL of 100 % ethanol was added and a centrifugation 
at 1000 g for 10 min at 4 oC was performed. The obtained pellet (histones) was washed 3 
times, each with 500 μL of cold PBS (Sigma-Aldrich, St. Louis, Missouri, USA) followed by 
centrifugation at 1000 g at 4 oC for 10 min. Lastly histones were resuspended in 100 μL of 
0.1 % PBS-Triton and stored at -20 oC until quantification.  
A.4.2. Histone quantification 
Before subsequent analyses, samples were sonicated for 50 cycles, with 100 % amplitude 
using a UP100H Ultrasonic Processor (Hielscher Ultrasound Technology, Teltow, Germany). 
Histones were quantified using the Pierce™ BCA Protein Assay Kit (Thermo Fisher 
Scientific, Waltham, USA) according the manufacturer’s instructions. This method is based 
on the reduction of Cu2+ to Cu1+ by proteins followed by colorimetric detection of Cu1+ by 
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BCA141. BCA readings were executed using a microplate reader ASYS Expert PLUS 
(LaboControle, Oeiras, Portugal).  
A.4.3. Western blotting 
Histone samples were diluted in loading buffer were denatured at 95 oC for 7.5 min in the 
thermocycler Swift™ Maxi® (ESCO®, Singapore). Subsequently, histone samples were 
loaded in a 20 % (w/v) SDS/polyacrylamide gel (Nzytech Company, Lisbon, Portugal) in a 
Mini-Protean® Tetra Vertical Electrophoresis Cell (Bio-Rad, California, USA), and ran under 
reducing conditions, according to the method described by Laemmli142. Electrophoresis 
conditions were maintained at 15 mA, per gel, connected to a PowerPac™ Basic (Bio-Rad). 
Histones were then electrotransferred onto a 0.45 μm pore membrane (Amersham 
Hybond™-P PVDF; GE Healthcare, Buckinghamshire, UK), which was stirred in 100 % 
methanol for about 20 seconds prior to use.  
The transference process was undertaken using a Mini Trans-Blot® Cell Kit (Bio-Rad), 
with cooled transfer buffer circulating at 600 rpm in a Heidolph MR 3001 agitator (Heidolph, 
Schwabach, Germany), at 124 mA for 45 min, and connected to a PowerPac™ Basic (Bio-
Rad). The transfer buffer consisted in 25 mM Tris-HCl pH 8.2 - 8.7, 192 mM glycine and 20 
% (v/v) methanol. 
Further, membranes were incubated in a 5 % blocking solution (1 % (w/v) milk fatty acids-
free diluted in TBS (14.2 % NaCl (w/v), 10 % Tris-HCl 1 M pH 7.5, (v/v)) with 0.1 % Tween® 
20 (v/v) (Sigma-Aldrich, St. Louis, USA), for 2 h in a Mini LabRoller™ Dual Format Rotator at 
RT (room temperature). TBS with 0.1 % Tween® 20 (v/v) was used to wash the membranes. 
Then, the membranes were incubated overnight at 4 oC with anti-rabbit Histone H3K27me3 
antibody (pAb) (1:500, Active Motif, Carlsbad, California, USA) using a Mini LabRoller™ Dual 
Format Rotator.  
After another washing with TBS with 0.1 % (v/v) Tween® 20, the membrane was 
incubated with anti-rabbit immunoglobulin G, HRP-linked antibody (1:2000, Cell Signaling 
Technology®, Danvers, MA, USA) for 1 h 45 min at RT in a Mini LabRoller™ Dual Format 
Rotator followed by washings (4 times) with TBS with 0.1 % Tween® 20 (v/v), in a Rocker 25 
agitator at 100 rpm, for 5 min each. Immunocomplexes were revealed using the 
Amersham™ ECL™ Prime Western Blotting Detection Reagent (GE Healthcare) in 1:1 
concentration, using the Chemidoc™ XRS+ System (Bio-Rad). 
The membranes were stripped off their antibodies in a Rocker 25 agitator at 100 rpm. 
Each step takes 5 min, involving a washing step with water, incubation with the stripping 
solution (25 % acetic acid (v/v), 0.5 % Tween® 20 (v/v), 0.05 % sodium dodecyl sulfate (w/v),  
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0.75 % glycine (w/v)), two series of washings with water, and one last washing with TBS with 
0.1% Tween® 20 (v/v). 
The membrane was blocked again and washed, as previously described above and was 
further incubated with anti-mouse Histone H3t antibody (mAb) (1:20000, Active Motif) 
overnight at 4 oC. After proper washing and incubation with peroxidase-conjugated anti-
mouse secondary antibody IgG+IgM (H+L) (1:4000, Jackson ImmunoResearch, West Grove, 
PA, USA), immunocomplexes were detected as previously described. 
All antibodies specified in this protocol are described in Table 1. 
 
Table 1. List of primary and secondary antibodies used in immunoblot assays. 
Antibody Brand Reference Dilution 
Histone H3K27me3 (Host: rabbit) Active Motif 39157 1:500 
Histone H3t (Host: mouse) Active Motif 39763 1:20000 
Anti-Rabbit IgG, HRP-linked Antibody 
Cell Signaling 
Technology® 
7074 1:2000 
Anti-Mouse: affinipure goat anti-mouse 
IgG+IgM antibody 
Jackson 
ImmunoResearch 
115-035-044 1:4000 
 
A.4.4. Image and Statistical analysis 
All images were captured using Quantity One® 4.6 software for Windows (Bio-Rad), 
exposing the membrane in the Chemidoc XRS+ System, using the chemiluminescent option 
for incubations with Histone H3t antibody, and the chemiluminescent high-sensitive option for 
incubations with Histone H3K27me3 antibody. Membrane expositions where stopped when 
the signal reached saturation point. 
Images where processed and analyzed by using ImageJ 1.48v software from National 
Institutes of Health, (USA); converted into 8-bit format. The percentage of H3K27me3 was 
normalized to H3t percentage. One way ANOVA followed by post hoc Bonferroni’s multiple 
comparison test was performed in GraphPad Prism version 5.00 for Windows, GraphPad 
Software, San Diego, California, USA, “www.graphpad.com”. 
 
B. In vivo studies: characterization of CVD patients and healthy individuals 
To determine whether EZH2 suppression and decrease of H3K27me3 content were 
associated with markers of hypomethylation and CVD, we studied plasma and PBMC from 
CVD patients and controls. 
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B.1. Participants and sample collection 
We studied 14 atherosclerotic vascular patients [mean age 56.08 ± SD 10.56 years] and 
15 healthy controls [mean age 52.63 ± SD 6 years]. The patients group was constituted by 4 
women and 10 men; the control group was constituted by 8 women and 7 men. Cases were 
recruited by Prof. Doutor Fausto Pinto’s team (Centro Hospitalar Lisboa Norte, Lisboa, 
Portugal) amongst patients who had been admitted to Hospital de Santa Maria, Lisbon, 
Portugal with a diagnosis of acute coronary syndrome; samples were collected at least 6 
months after the occurrence. Controls were selected among staff of the Faculty of Pharmacy 
from the Universidade de Lisboa whose lifestyle details (i.e., alcohol consumption, 
medication, smoking, physical exercise, and personal, and family histories) were established 
by use of standardized questionnaires and protocols. The criteria for inclusion in the control 
group were: normal hematology and liver/renal function tests and no history of vascular 
pathology. Exclusion criteria for both groups were metabolic, hepatic, or renal pathology; 
cancer; alcohol or drug abuse. All patients, but none of the controls, were under therapy with 
the following drugs: non-steroidal anti-inflammatory + antiplatelet + angiotensin converting 
enzyme (ACE) inhibitors + statins. Written informed consent was obtained from all 
participants, and the study was approved by Local Ethical Committees. 
B.2. Preparation of biological samples 
A total of 50 mL of EDTA-blood samples were collected after a fast of 12 h; plasma and 
PBMCs were isolated no more than 4 h after the blood collection66. We used 10 mL of blood 
for plasma separation by centrifugation at 1800 rpm at 8 oC for 10 min, using an Eppendorf 
5810R centrifuge (Eppendorf). From the obtained plasma, 750 μL were immediately 
prepared to preserve SAH and SAM by adding 750 μL of 10 % perchloric acid (v/v). The 
remaining plasma was further used to perform the biochemical analysis detailed in section 
B.3. All preparations were stored at −80 oC until use. From the remaining blood, PBMC were 
immediately isolated using density gradient centrifugation (section B.2.1). The obtained cells 
were further used to measure intracellular SAM/SAH levels (section A.3) and to isolate 
histones and RNA (section B.2.2) for the studies detailed in B.3 and B.4, respectively.   
B.2.1. PBMC isolation 
PBMC were isolated from the blood samples by density gradient centrifugation143, using 
LEUCOSEP™ tubes (Greiner Bio-One GmbH, Kremsmünster, Austria), that were put on ice 
and filled up to the filter with Ficoll-Paque™ PLUS (GE Healthcare, Buckinghamshire, UK). 
After homogenizing carefully, the EDTA-blood was layered on the LEUCOSEP™ tubes and 
centrifuged at 2700 rpm for 20 min, with no brake. Differential migration during centrifugation 
resulted in the formation of layers, containing different cell types143, as illustrated in Figure 5. 
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The bottom layer contains red blood cells and granulocytes, and the layer above contains the 
Ficoll-Paque™ PLUS solution. Because of their lower density, PBMC were found at the 
interface between the plasma and the Ficoll-Paque™ PLUS solution143. 
The PBMC were recovered with a plastic sterile Pasteur pipette (FL Medical, Torreglia, 
Italy) and were divided into two 15 mL Cellstar® tubes (Greiner Bio-One GmbH). The tubes 
are centrifuged at 4000 rpm for 7 min at 8 oC. The supernatant was discarded and 3 mL of 
Hanks Solution (Sigma-Aldrich) was added to the PBMC pellets. The tubes were centrifuge 
again, in the same conditions as previously described, and the supernatant was discarded. 
All centrifugations up to this point were executed in an Eppendorf 5810R centrifuge 
(Eppendorf).  
Figure 5. Isolation of leukocytes from EDTA-blood using Ficoll-Paque™ density gradient centrifugation. 
Abbreviations: PBMC, peripheral blood mononuclear cells. 
Adapted from reference
144
. 
 
The PBMCs’ pellets were washed twice with 750 μL of Hanks Solution, and then 
transferred into a 2 mL sterile microtube (Eppendorf). After a centrifugation at 12000 rpm for 
20 seconds, the supernatant discarded and 750 μL of cold DEPC-treated water were added 
to ressuspend the pellet, and another 750 μl of Hanks solution were added to the microtubes, 
which were centrifuged again in the same conditions. These last two centrifugations were 
executed in a Hermle Z233M-2 centrifuge (Labnet International, Inc). 
100 μL of cold PBS were added to one of the microtubes, which was immediately frozen at 
-80 oC until further SAM/SAH determinations (after immediate deproteinization with 200 μL of 
10 % perchloric acid (v/v)). To the other microtube, 1000 μL of RNAlater® solution (Ambion, 
ThermoFisher Scientific, Waltham, USA) was added, and followed by an overnight incubation 
at 4 oC. The microtube was stored at -80 oC, until further histone and RNA extractions, as 
detailed in section B.2.2.1 and B.2.2.2. 
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B.2.2. Isolation of histones and RNA 
A methodological approach illustrated in Figure 6 was optimized in order to allow the 
isolation of histones and RNA from the same PBMC sample conserved in RNAlater® solution 
(Ambion) or in PBS. 
For PBMC conserved in RNAlater® solution, 500 μL of cold PBS (Sigma-Aldrich) were 
added, followed by a centrifugation at 2500 g for 10 min in an Eppendorf 5810R centrifuge 
(Eppendorf). After discarding the supernatant, 1000 μL of HLB were added to the PBMC, 
which were incubated for 30 min on ice in a Rocker 25 agitator (Labnet International, Inc). 
Afterwards, the samples were centrifuged at 10000 g for 10 min at 4 oC. The obtained pellet 
was further used for histone extraction by adding 50 μL of 0.25 M H2SO4, whereas the 
supernatant was transferred to another 2 mL sterile microtube (Eppendorf), and kept on ice, 
until RNA extraction.  
 
Figure 6. Simplified scheme of RNA and histone extractions executed from the same sample of PBMC. 
Abbreviations: HLB, hypotonic lysis buffer. 
 
B.2.2.1. RNA extraction 
To the supernatant obtained in B.2.2., 1 mL of Isol-RNA lysis Reagent (5 PRIME, Hilden, 
Germany) was added. After 5 min at RT, 200 μL of chloroform was added; the microtubes 
were agitated and incubated at RT for 2 min. During this incubation period, a separation into 
phases occurred: RNA remain in the aqueous phase, proteins stay down in the organic 
phase, in between stands DNA145. The tubes were then centrifuged at 4 oC for 15 min at 
12000 rpm and the obtained supernatant, approximately 500 – 700 μL, was transferred to a 
new 2 mL sterile microtube (Eppendorf). An equal volume of 100 % isopropanol was added 
for RNA precipitation and after 10 min at RT, the tubes were centrifuged for 10 min at 4 oC at 
12000 rpm and the supernatant was discarded. RNA pellet was washed with 1 mL 75 % 
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ethanol in DEPC-treated water (v/v), followed by 5 min centrifugation at 4 oC at 12000 rpm. 
Lastly, the supernatant was discarded and the tubes were left to dry at RT, in an upside-
down position. Then 50 – 100 μL of DEPC-treated water, and after 10 min incubation at RT, 
the tubes were stored at -80 oC. 
B.2.2.2. Histone extraction 
After RNA extraction, we proceed to histone extraction by adding 200 μL of 100 % ethanol 
and following the protocol as described in section A.4.1. 
B.3. Biochemical analysis 
Part of the plasma (1 mL) obtained in B.2. was sent to the laboratory of NPSB (Núcleo de 
Prestação de Serviços de Bioquímica, FFULisboa) for determination of the levels of total 
cholesterol, HDL-c, LDL-c, triglycerides, and tHcy (total homocysteine). The remaining 
plasma was sent to Dr. Joaquim Chaves Laboratories (JCLab, Algés) to determine the 
concentrations of the following parameters: fibrinogen, CRP, apoB-100, apoA-I, IL-1β, ICAM-
1, and VCAM-1. Details about the methodology used at NPSB and at JCLab are shown in 
Table 2.  
SAH and SAM were measured in the deproteinized PBMC extracts obtained in B.2. using 
the same procedures described in section A.3.  
B.3.1. Statistical analysis 
Unpaired Student’s T-test with Welch’s correction was performed to compare differences 
between control and patients groups, with the accepted value of P<0.05 as significant, using 
GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA, 
“www.graphpad.com”. 
B.4. Western blot analysis and statistical analysis 
The histones obtained in B.2. were used for Western blot studies to analyze H3K27me3 
and histone H3 contents, as described in section A.4.3. 
Unpaired Student’s T-test with Welch’s correction was performed to compare differences 
between control and patients groups, with the accepted value of P<0.05 as significant, using 
GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, California, USA, 
“www.graphpad.com”. 
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Table 2: Resume table of the parameters analyzed in the blood. 
Parameter Method 
Volume of 
plasma 
Location 
TC Enzymatic endpoint146 from Randox CH 200 10 μL NPSB 
HDL-c Precipation method52 from Randox CH 203 10 μL NPSB 
LDL-c 
Calculated based on the levels of total cholesterol, HDL-c, 
and triglycerides147. 
- NPSB 
Triglycerides  GPO-PAP148 from Randox TR210 10 μL NPSB 
tHcy High-performance liquid chromatography (HPLC)149 100 μL NPSB 
Fibrinogen 
Fibrinogen bindarid™ radial immunodiffusion kit (The Binding 
Site Group, Birmingham, United Kingdom)59 
10 μL JCLab 
CRP 
Latex-enhanced immunoturbimetric assay in Siemens Advia® 
1650 chemistry analyzer (Siemens Healthcare)150 
10 μL JCLab 
apoB-100 
Immunoturbidimetry enhanced by polyethylene glycol (PEG) 
in Siemens Advia® 1650 chemistry analyzer (Siemens 
Healthcare)151 
10 μL JCLab 
apoA-I 
Immunoturbidimetry enhanced by polyethylene glycol (PEG) 
in Siemens Advia® 1650 chemistry analyzer (Siemens 
Healthcare)151 
10 μL JCLab 
IL-1β 
Enzyme Amplified Sensitivity 
Immunoassay152 (DIAsource IL-1β-EASIA from DIAsource 
ImmunoAssays S.A.) 
200 μL JCLab 
ICAM-1 
Enzyme immunoassay for the quantitative determination of 
soluble 
VCAM-1153 (sVCAM-1 ELISA 
-Enzyme from ILB international) 
30 μL JCLab 
VCAM-1 
Enzyme immunoassay for the quantitative determination of 
soluble 
ICAM-1153 (sICAM-1 ELISA 
-Enzyme from ILB international) 
30 μL JCLab 
Abbreviations: NPSB, núcleo de prestação de serviços de bioquímica, FFULisboa; JCLab, Dr. Joaquim Chaves 
Laboratories; TC, total cholesterol,; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein 
cholesterol; tHcy, total homocysteine; CRP  C-reactive protein; apoB-100, apoliprotein B-100; apoA-I, apoliprotein 
A-I; IL-1β, interleukin-1 β; ICAM-1, intercelular adhesion molecule 1; VCAM-1, vascular adhesion molecule 1. 
B.5. RT-qPCR 
RNA is an unstable molecule and its half-life is very short so it is important to ascertain a 
good RNA quality and integrity beyond extraction, which depends on the quality of cell 
lysis140. RNA integrity was verified by 1 % SeaKem® LE agarose (Lonza) gel electrophoresis 
(data not shown), and its quality and quantity were evaluated on NanoDrop ND-100 
spectrophotometer (NanoDrop Products, Wilmington, DE, USA) using NanoDrop 1000 
Operating Software (version 3.7.1 compatible with Windows). Moreover, possible 
contamination with genomic DNA was eliminated by treatment with deoxyribonuclease I, 
DNase I recombinant, RNAse-free 10U/μL (Roche, Basel, Switzerland). Briefly, 1 μg of total 
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RNA were made up to 7 μL with DEPC-treated water and 0.25 U of DNase I was added in 
the laminar flow chamber. The mixture was incubated for 15 min at 25 oC in the 
thermocycler. The reaction was stopped by adding 1 μL 80 mM EDTA and further incubated 
for 10 min at 75oC.  
The resulting DNase I-treated RNA samples were reverse transcribed using the Super 
Script® III First-Strand Synthesis Super Mix (Invitrogen Life Technologies by ThermoFisher 
Scientific, Waltham, USA), adding 10 μL of reaction buffer and 2 μL of enzyme mix to the 8 
μL sample and incubated for 10 min at 25 oC, 30 min at 50 oC, and 5 min at 85 oC. Then 
added 1 μL of RNAse H was added and the tubes were incubated at 37 oC for 20 min.  
Afterwards, the samples were put on ice and were quantified on NanoDrop ND-1000 
spectrophotometer (NanoDrop Products), using NanoDrop 1000 Operating Software (version 
3.7.1 compatible with Windows), to assure that the amount of DNA template was similar 
amongst different samples.  
All incubations were performed in the thermocycler Swift™ Maxi® (ESCO®).  
First-strand cDNA (250 ng) was used as template for qPCR using a CFX96™ Real-Time 
System C1000 Touch™ thermocycler (Bio-Rad), programed by Bio-Rad CFX Manager 3.0 
for Windows with the following cycling conditions: 50 oC for 2 min, 95 oC for 10 min, and 40 
cycles 95 oC for 15 s followed by 60 oC for 1 min.  
Gene expression analyses were performed using the TaqMan® Gene Expression Assays 
(Applied Biosystems by Thermo Fisher Scientific, Waltham, MA, USA) IDs: Hs00544833_m1 
for EZH2 and Hs015555410_m1 for IL-1β and as endogenous control the TaqMan β-actin 
Control Reagents (4352935 - 1104025). In every reaction the TaqMan Gene Expression 
Master Mix was used following enclosed instructions. The plaques were centrifuged at 500 g 
for 3 min at 4 oC in Eppendorf 5810 R V6 centrifuge (Eppendorf) before the amplification. 
Each sample was assayed in triplicate and results represent a minimum of three 
independent experiments. Relative expression of target mRNA was calculated from the 
target Ct values and β-actin mRNA Ct values, using the comparative CT method (ΔΔ CT 
Method).  
B.5.1. Statistical analysis 
Unpaired Student’s T-test was performed to compare differences between the control and 
patients groups, with the accepted value of P<0.05 as significant, using GraphPad Prism 
version 5.00 for Windows, GraphPad Software, San Diego, California, USA, 
“www.graphpad.com”. 
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IV – RESULTS AND DISCUSSION 
A. In vitro studies: incubation procedure in endothelial cells 
A.1. Influence of ADA in H3K27me3 on HUVEC cells  
HUVEC are vulnerable to high SAH levels, which can affect the cellular methylation 
pattern135. We wanted to investigate if hypomethylation, induced by SAH accumulation, 
influenced the content of the histone epigenetic mark, H3K27me3. To test this, we incubated 
HUVEC in the presence and absence of ADA, as this compound inhibits SAH hydrolysis, 
thus increasing intracellular SAH levels154. Plus, SAH hardly crosses the cell membrane, so 
SAH build-up due to ADA treatment is quite effective33.  
To confirm the efficacy of ADA to trigger cellular hypomethylation, we quantified SAH and 
SAM levels, as well as SAM/SAH ratio, an indicator of the cellular methylation status67. 
Actually, we observed a dramatic increase of intracellular SAH levels in HUVEC treated with 
20 μM ADA after 24 h, when compared to control cells (1797 vs 142.5 pmol/mL, 
respectively), whereas SAM levels only increased from 396.4 to 709.5 pmol/mL, respectively. 
However, after 48 h of incubation, SAH levels decreased to 416.5 pmol/mL and to 126.9 
pmol/mL in treated and in control cells, respectively, whereas SAM levels decreased to 105.9 
and 259.1 pmol/mL, respectively. Accordingly, as illustrated in Figure 7, at 24 h the 
SAM/SAH ratio of cultured cells incubated in the presence of 20 μM ADA revealed a 7-fold 
reduction when compared with control cells, thus proving the impaired methylation status of 
the cellular environment.  
Figure 7. Intracellular SAM/SAH ratio in HUVEC incubated with ADA 0 μM and 20 μM for 24 h and 48 h. 
Abbreviations: ADA, adenosine-2,3-dialdehyde; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; 
HUVEC,  human umbilical vein endothelial cells. 
These results clearly showed that under physiological conditions, SAM and SAH levels are 
strictly regulated, showing a narrow variation. After treatment with ADA, SAH levels increase 
dramatically whereas SAM levels’ variation is much more restricted, suggesting a tight 
regulation. 
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We then quantified H3K27me3 content in control and ADA-treated HUVEC and our results 
showed that, after 24 h incubation with 20 μM ADA, a significant reduction of relative 
H3K27me3 levels occurred, as illustrated in Figure 8.  
Figure 8. Effect of excess of SAH on H3K27me3 mark in HUVEC.  
(A) Western blot images of H3K27me3 (17 kDa) and H3t (17 kDa) content in HUVEC, upon incubation with 0 μM 
or 20 μM ADA for 24 h and 48 h. (B) Results correspond to mean ± SD (n=3) upon H3K27me3 content 
normalization against H3t. Significant difference was inferred at *p<0.05 vs 0 μM ADA at 24 h using one way 
ANOVA followed by post hoc Bonferroni’s multiple comparison test. 
Abbreviations: ADA, adenosine-2,3-dialdehyde; H3K27me3, trimethylation of histone H3 at lysine 27; H3t, histone 
H3 total; SAH, S-adenosylhomocysteine; HUVEC,  human umbilical vein endothelial cells. 
 
However, in HUVEC incubated with 20 μM ADA, after 48 h the H3K27me3 relative levels 
are similar to the ones observed in control cells. A plausible explanation for this observation 
is the decay in ADA efficiency along the incubation time, and that enzymatic SAHH activity 
can be recovered. Effectively, ADA inhibiting activity may not survive beyond 24 h because 
of its two labile aldehyde groups155. In addition, as we previously referred, we observed a 
dramatic impairment of SAH levels at 48 h, and these lower levels of SAH do not seem to be 
sufficient to inhibit the activity of the methyltransferase responsible for the trimethylation of 
the H3K27, thus explaining the increase of the H3K27me3 levels, which reached values 
similar to the control cells. An increase in SAH, independent from SAM decrease, is a more 
powerful predictor of cellular methylation decrease156. Nevertheless, this experience proved 
that, in vitro and after 24 h incubation, an increase of SAH levels does alter the cellular 
methylation status, leading to a decrease of the epigenetic mark H3K27me3. 
In line with these observations, our group previously described that elevated SAH levels 
induces H3K27me3 hypomethylation in human coronary artery endothelial cells (HCAEC)89. 
The same study also showed that intracellular SAH accumulation can also lead to cytokine 
production, like IL-1β, through NF-κB pathway activation89, which is a primed inflammatory 
pathway in atherosclerosis157. This pathway has an important role in initiation and 
development of atherosclerosis and can lead to the induction of pro-apoptotic genes, 
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depending on the cell type158. Hcy has a pathogenic effect through oxidative stress increase, 
which could result in apoptosis154, via NF-κB activation159. 
Another study with cultured EC demonstrated that high levels of Hcy, which leads to 
increased intracellular SAH levels, result in cell growth arrest through gene 
hypomethylation160.  
Another interesting study with HUVEC showed that intracellular SAH accumulation, 
triggered by 3-deazaadenosine (DZA), another SAH hydrolase inhibitor, led to inhibition of 
cellular growth and proliferation, morphological alterations, and apoptosis. Furthermore, it 
also resulted in global DNA hypomethylation161. Our group also observed cell growth 
decreased upon ADA treatment in HCAEC89. This suggests that intracellular SAH 
accumulations may also cause other damages to EC, besides the alterations to the cell 
methylation pattern. Our group also observed NO decreased bioavailability in cultured 
human EC under excess of SAH89. NO is a vital compound for normal endothelial functions33, 
and whose decreased bioavailability is a hallmark of ED.  
 
B. In vivo studies: characterization of CVD patients and healthy individuals 
B.1. Quantification of Hcy levels and SAM/SAH ratio  
In the past decades, many studies have linked high levels of plasma Hcy to CVD 
risk87,162,163. Hcy levels differ between gender; men tend to have higher Hcy levels than 
women, although levels rise in women when they reach menopause66. These differences in 
gender are explained by men’s larger muscle mass, and by the hormonal estrogen therapy in 
women164, which has shown to affect CVD risk165. Additionally, the metabolism of Hcy is 
more efficient in women than in men66. 
Our results revealed that plasma tHcy concentration (mean ± SD) was higher in CVD 
patients than in controls (11.09 ± 2.3 μM and 8.41 ± 2.80 μM, respectively), though not 
reaching statistical significance. Furthermore, as shown in Figure 9, we stratified our results 
according to gender. Control men presented higher plasma tHcy levels than control women 
(9.47 ± 2.96 μM and 7.35 ± 2.20 μM, respectively), though the difference did not reach 
statistical significance. Amongst CVD patients, no difference in tHcy levels was observed 
between men and women (11.14 ± 2.46 μM and 10.95 ± 2.20 μM, respectively). 
Nevertheless and interestingly, CVD women presented statistically significant higher tHcy 
plasma levels than control women (10.95 ± 2.15 and 7.35 ± 2.20, respectively), whereas 
such difference was absent between CVD and control men (11.14 ± 2.46 and 9.47 ± 2.96, 
respectively). On average, all groups have normal tHcy levels, which range from 5 to 15 μM 
(in a fasting state)1. 
IV  – RESULTS AND DISCUSSION 
30 
 
 
Figure 9. Evaluation of tHcy levels by gender in the plasma.  
Results correspond to mean ± SD. Significant difference is inferred at *p<0.05 vs control using unpaired Student’s 
T test with Welch’s correction.  
Abbreviations: tHcy, total homocysteine. 
 
Results from the Hordaland Homocysteine Study showed that smoking and large caffeine 
consumption are associated with high levels of Hcy1. In fact, smoking can influence folate 
absorption, contributing to the elevation of Hcy levels due to impaired remethylation166. Since 
64 % of the CVD population has smoking history, compared with 44 % of the controls, 
smoking might have influenced our results. 
Figure 10. Evaluation of tHcy, SAM/SAH ratio in PBMC and in plasma in the studied population.  
Results correspond to mean ± SD. Significant difference is inferred at *p<0.05 vs control using unpaired Student’s 
T test with Welch’s correction.  
Abbreviations: tHcy, total homocysteine; SAM, S-adenosylmethionine, SAH, S-adenosylhomocysteine; PBMC, 
peripheral blood mononuclear cells; Pl, plasma. 
 
SAH plasma levels have been suggested to be a better CVD risk indicator than Hcy88, thus 
we also measured SAM and SAH levels as well as SAM/SAH ratio in both PBMC and in 
plasma of the studied populations. Our results, displayed in Figure 10, showed that the 
PBMC SAM/SAH ratios were significantly lower in CVD patients than in controls (12.21 ± 4 
and 16.2 ± 4.63, respectively). However, the correspondent difference in plasma SAM/SAH 
ratios did not reached statistical significance (7.56 ± 2.2 and 9.17 ± 2.31, respectively), 
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although it was previously shown that an increase of plasma tHcy was associated with an 
increase of plasma SAH levels156. As aforementioned, SAH is the precursor of Hcy that 
accumulates when Hcy accumulates167. We reason that evaluating SAM/SAH levels in 
PBMC is a more reliable measure of the extent of atherosclerosis, as these cells directly 
participate in endothelial inflammatory response. 
 
We have also investigated the relation between circulating tHcy and SAM/SAH ratio either 
in PBMC or in plasma of CVD patients and controls, but we found the absence of statistical 
significance. Our results demonstrated a wide range of PBMC SAM/SAH values in both 
studied groups (Figure 11A) whereas the correspondent plasma values were much less 
dispersed (Figure 11B). Nevertheless, as can be observed in Figure 11A, where we 
correlated tHcy levels with PBMC SAM/SAH ratio, the controls values are spotted in the 
upper-left quadrant, corresponding to the lower levels of tHcy and the higher SAM/SAH 
ratios. Conversely, CVD patient values presented a tendency to higher tHcy levels and lower 
SAM/SAH ratios. Concerning the correlation between tHcy levels and plasma SAM/SAH 
ratios, displayed in Figure 11B, the values of both studied groups are condensed in the lower 
quadrants, revealing lower SAM/SAH ratios and thus confirming the absence of the 
statistically significant differences previously described between CVD patients and controls 
(Figure 11B).  
Figure 11. Plot of individual values of plasma tHcy vs SAM/SAH ratio. 
(A) Distribution of individual values of tHcy vs and SAM/SAH ratio in the plasma. (B) Distribution of individual 
values of tHcy vs SAM/SAH ratio in the PBMC. 
Abbreviations: tHcy, total homocysteine; SAM, S-adenosylmethionine, SAH, S-adenosylhomocysteine; PBMC, 
peripheral blood mononuclear cells; Pl, plasma. 
 
Interestingly, when CVD patient and control values were taken together, we could observe 
a weak inverse correlation (r = - 0.20) although non-significant, between circulating tHcy 
levels and plasma SAM/SAH ratios, since we were measuring components in the same fluid. 
Furthermore, tHcy levels did not correlate with PBMC SAM/SAH ratios. We hypothesize that 
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a similar trend would be observed if the correlation was achieved with intracellular tHcy 
levels. 
Finally, we correlated the SAM/SAH ratios in PBMC and plasma and, though no 
statistically significant correlation was detected (r = 0.29), our results showed that an 
increase of SAM/SAH values in the plasma was accompanied by an elevation of the 
SAM/SAH ratio in the PBMC, as illustrated in Figure 12.  
 
 
Abbreviations: tHcy, total homocysteine; SAM, S-adenosylmethionine, SAH, S-adenosylhomocysteine; PBMC, 
peripheral blood mononuclear cells; Pl, plasma. 
 
 
We also compared SAH levels in the plasma and PBMC in both studied groups, and the 
results revealed CVD patients have higher levels in the plasma and in PBMC than controls 
(Figure 13). Nevertheless, these results must be analyzed carefully since the absolute SAH 
levels were not normalized to total protein values. Interestingly, SAH values are higher in 
plasma than in PBMC, reaching a statistical significance in controls, but not in patients (data 
not shown). These observations are in concordance with the SAM/SAH ratios that we 
calculated above, since low SAM/SAH ratios correspond to higher levels of SAH, in the CVD 
patients group compared with controls, both in PBMC (12.21 ± 4 and 16.20 ± 4.63, 
respectively), and in plasma (7.56 ± 2.20 and 9.17 ± 2.31, respectively). 
Our results confirmed previous reports stating that circulating tHcy level is a good indicator 
of CVD risk. However, and concerning the methylation index (SAM/SAH ratios) the present 
results clearly suggested that intracellular measurements are a more reliable parameter than 
plasma levels.  
 
 
 
 
Figure 12. Plot of individual values of SAM/SAH ratios in the plasma vs SAM/SAH ratio in the PBMC. 
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Abbreviations: SAM, S-adenosylmethionine, SAH, S-adenosylhomocysteine; PBMC, peripheral blood 
mononuclear cells; Pl, plasma. 
 
B.2. Evaluation of cardiovascular risk parameters in the population 
B.2.1. Evaluation of pro-atherogenic indicators in circulating plasma 
Atherosclerosis is an inflammatory disease that begins with ED and progresses through 
lipid accumulations in the vascular wall; therefore, we used the levels of several circulating 
lipids to characterize our population, namely: triglycerides, total cholesterol, HDL, LDL, apo-
AI, and apoB-100. Our results are shown in Figure 14. 
Figure 14. Levels of plasma circulating lipids in the studied population.  
Results correspond to mean ± SD. Significant difference is inferred at *p<0.05;**p<0.01;***p<0.001 vs control 
using unpaired Student’s T test with Welch’s correction.  
Abbreviations: HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; apo-AI, 
apolipoprotein AI; apoB-100, apolipoprotein B-100; CVD, cardiovascular disease. 
Figure 13. Evaluation of SAH levels in the studied population. 
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 Triglycerides  
In our study, the triglyceride plasma values were 124.03 ± 30.98 mg/dL for CVD patients, 
and 101.26 ± 40.97 mg/dL for controls; we did not find any statistical difference between both 
groups. 
Various studies have demonstrated that high triglyceride levels are associated with high 
rates of CV events and deaths168. Other authors claim that triglyceride measurement does 
not give information about immediate CVD risk169. Accordingly, a recent study has shown 
that elevated levels of triglycerides are associated only with increased long-term mortality of 
coronary heart disease patients170. Nevertheless, triglycerides do not accumulate in the 
atherosclerotic plaque, as they are degraded in various cells in the body171. 
 
 Total cholesterol 
Our results showed that total cholesterol plasma levels are significantly lower in the patient 
group (127.52 ± 24.86 mg/dL) than in controls (175.89 ± 21.53 mg/dL). 
Cholesterol builds in the vessel’s wall and participates in the atherosclerosis progression43, 
and it is considered a CVD risk factor172. Also, high levels of circulating Hcy can induce 
cholesterol accumulation50, and since tHcy levels are higher in patients it would be expected 
that cholesterol levels would have the same tendency. However, all CVD patients were 
subjected to cholesterol lowering therapy, like statins, which may explain these unexpected 
findings, as it will be discussed further below. 
The cholesterol can be carried by HDL and LDL, labeled as HDL-cholesterol (HDL-c) and 
LDL-cholesterol (LDL-c)173. LDL-c is a measure of total cholesterol that exists in LDL, 
whereas HDL-c is a measure of total cholesterol that exists in HDL174. 
 
 LDL-c and HDL-c 
CVD patients displayed decreased LDL-c plasma levels (70.11 ± 20.95 mg/dL) when 
compared to the control group (89.04 ± 20.95 mg/dL). Moreover, HDL-c levels are also 
significantly lower in CVD patients (34.64 ± 8.29 mg/dL) than in controls (63.22 ± 11.46 
mg/dL). 
Subjects with high CVD risk usually present high plasma levels of LDL-c175. In fact, high 
LDL-c levels are significantly linked to atherosclerosis44 as they can promote inflammation65. 
Endothelial membrane permeability for LDL is enhanced in case of an atherosclerotic lesion 
and, as a consequence, LDL-c enters into the vascular intima. Modified LDL, like ox-LDL, 
can be easily phagocytosed by macrophages resulting in their accumulation in vascular cells, 
and causing local changes to the arterial wall176,177. These include increased adherence 
ability of monocytes18 and the establishment of an inflammatory phenotype, a process that 
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facilitates apoptosis through NF-κB pathway activation, thus perpetuating the pathological 
lesion178.  
As opposed to LDL, HDL has a protective vascular role by removing the excess of 
cholesterol from peripheral tissues43, diminishing the levels of adhesion molecules on EC, 
enhancing the synthesis of NO, and preventing LDL oxidation51.  
 
Lipid lowering drugs are the first line of attack towards atherosclerosis179. Statin treatment, 
due to its cholesterol and LDL-c lowering effects, is a normal therapeutic approach for 
atherosclerosis and individuals with high CVD risk175. Statins function by inhibiting the 
enzyme HMG-CoA reductase that partakes in the cholesterol synthesis pathway. As a result 
of this drug intake, there is decreased intrahepatic cholesterol levels and an up-regulation of 
LDL receptors in hepatic cells, leading to increase LDL uptake from the circulation174. 
Pleiotropic effects of statins include anti-thrombotic and antioxidant effects on the vessels180. 
Interestingly, high HDL-c levels are claimed as a good indicator of cardiovascular risk in 
statin-treated patients that have LDL-c in low levels168. 
In addition to statins, the antiplatelet effect of aspirin (acetylsalicylic acid) is also used in 
the prevention of acute myocardial infarction. Aspirin inhibits platelet activation and 
aggregation, reduces thrombosis and inhibits the progression of atherosclerosis, by inhibiting 
LDL-c oxidation181 and reducing LDL circulating levels177.  
Aspirin has antithrombotic effects through the inhibition of cyclooxygenase inhibition and 
prostangladin reduction, ultimately resulting on platelet aggregation inhibition, without 
affecting EC functions182. Aspirin has been shown to have cytoprotective functions that are 
unrelated with its antiplatelet activity, such as improving endothelium-dependent arterial 
relaxation by inducing the release of NO from the vascular endothelium183, and reducing 
apoA levels in human hepatocytes by suppressing apoA gene transcription184. Clopidogrel, a 
drug that also inhibits platelet aggregation through a diverse mechanism is often associated 
with aspirin185, to avoid atherosclerosis progression. 
Atorvastatin also improves vascular NO bioavailability186. It leads to structural and 
metabolic modifications in HDL, enhancing HDL anti-atherogenic functions187. Besides HDL 
modulation, atorvastatin can also lead to LDL-c decrease179. 
ACE inhibitors, a therapy also given to the studied patients, can reduce the expression of 
LOX-1, the human receptor of ox-LDL, thus slowing down the atherosclerosis development. 
ACE or kininase II is an endothelial enzyme, which has a role in the balance of vasodilatation 
and constriction188. 
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Our results showed that CVD patients display decreased LDL levels compared with 
controls, an unexpected finding that may well be a consequence of the medication of the 
CVD patients. In fact, all patients were submitted to statins and aspirin therapy. The 
significant lower HDL-c levels in the CVD patient group, when compared to controls, 
confirmed that HDL-c levels are a good indicator of cardiovascular risk in statin-treated 
patients that have LDL-c in low levels.  
 
Interestingly, smoking has been linked with a decrease in HDL levels31, which might 
contribute to our results, as some patients have a smoking history.  
 apoA-I and apoB-100 
Concerning apoA-I and apoB-100 levels, we observed that the plasma concentration of 
these molecules is lower in the patient group than in controls (131.50 ± 18.50 mg/dL vs 
157.07 ± 13.14 mg/dL for apoA-I and 69.79 ± 12.61 mg/dL vs 84.60 ± 12.90 mg/dL). This 
observation corroborates our results from HDL-c and LDL-c measurements, since apoA-I is 
the major component of HDL, and apoB-100 is the major component of LDL18,51. Smoking 
seems to decrease apoA-I (and HDL-c) levels189. Furthermore, as we stated previously, 
aspirin reduces mRNA apoA levels in human hepatocytes184, which could have influenced 
the patients’ apoA-I levels. 
It was reported that Hcy levels correlate inversely with HDL-c and apoA-I levels in case of 
HHcy93, since Hcy can influence independently apoA-I levels189. Our results seem to follow 
that tendency as well.  
B.2.2. Evaluation of CVD risk in the population 
The CVD risk is the probability of developing the disease and it is calculated in accordance 
to physical manifestations, family history, and routine blood analysis190. These include the 
calculation of different ratios of lipids. It was reported that about 50 % of population with 
abnormalities in the lipoprotein metabolism are in risk to develop a CVD191.  
In our study we used total cholesterol/HDL-c and LDL-c/HDL-c ratios as indicators of 
cardiovascular risk192,193. Normal values for total cholesterol/HDL-c value are under 5 in men 
and under 4.5 in women, and for LDL-c/HDL-c ratio are under 3.5 in men and under 3 in 
women191. 
Our results, illustrated in Figure 15A, confirmed that amongst controls, most individuals are 
CVD risk free, for the exception of subjects 11, 14, and, 18. For presenting CVD risk, these 
individuals were excluded from our initial control group. Interestingly subject number 9 has 
really low values in both lipid ratios, comparing with the rest of the control individuals. These 
results could be due to the simvastatin therapy taken at the time. Simvastatin can lead to a 
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decrease in LDL-c levels168. Control number 15, who also displayed low LDL-c levels, did not 
state any medication in the questionnaires. 
Concerning CVD patients, and surprisingly, most individuals are not inserted in the CVD 
risk category, with the exception for individuals 1, 5, 9, and, 10 (Figure 15B).  
We argue that this unexpected finding is explained by the lipid lowering medication to 
which CVD patients were subjected to alter total cholesterol/HDL-c and LDL/HDL-c ratios173.  
Figure 15. CVD risk analysis in the studied population.  
(A) CVD risk distribution along the control group given by total Ch/HDL and LDL/HDL ratios. (B) CVD risk 
distribution along the CVD patient group given by total Ch/HDL and LDL/HDL ratios. 
Abbreviations: Ch, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; CVD, cardiovascular 
disease. 
We also compared the lipid ratios in the patient group vs controls but they were not 
statistically different (data not shown), showing the inefficacy of these blood lipids ratios as 
tools to identify high-CVD risk people for secondary prevention.  
Another estimate of the CVD risk, besides the referred total cholesterol/HDL-c and 
LDL/HDL ratios, is the calculation of the apoB-100/apoA-I ratio191. Thus, we have also 
calculated this ratio (data not shown) but none of the studied individuals could be inserted in 
the CVD risk category. This is not surprising, considering that LDL/HDL-c and total 
cholesterol/HDL-c ratios have a greater predictive value and are used for a long time, 
including in the Framingham Heart Study, as in opposition of apoB-100/apoA-I ratio173,191. 
B.2.3. Quantification of pro-inflammatory indicators 
As referred above, the atherosclerosis is an inflammatory disease of the vascular wall. 
Therefore, IL-1β, CRP, and fibrinogen were chosen as inflammatory indicators and were 
evaluated in CVD patients and in controls. Our results are shown in Figure 16. 
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Figure 16. Inflammatory parameters in the studied population.  
Results correspond to mean ± SD. Significant difference is inferred at *p<0.05 vs control using unpaired Student’s 
T test with Welch’s correction. 
Abbreviations: CVD, cardiovascular disease; IL-1β, interleukin-1β; CRP, C-reactive protein. 
 
 IL-1β 
IL-1β is an important pro-inflammatory cytokine, which partakes in the establishment and 
progression of atherosclerotic lesions. It has been reported that atherosclerosis patients 
show higher levels of IL-1β than healthy individuals194. Interestingly, Met&Gen Group 
observed that SAH accumulation in human EC activates NF-κB pathway, triggering IL-1β 
expression89. Nevertheless, our results showed that plasma IL-1β levels were lower in CVD 
patients (5.36 ± 0.73 pg/mL) than in controls (9.13 ± 4.73 pg/mL) although a high standard 
deviation of values was observed in the control group. However, we reason that, concerning 
the CVD patients, the anti-inflammatory therapy, like statins and high doses of aspirin, does 
inhibit cytokines release179,186, explaining this observation. Also, accumulated cholesterol 
may induce IL-1β expression195, and thus we speculate that the low cholesterol levels in CVD 
patients also contributed to the low levels of IL-1β. 
 
 CRP 
CRP is an acute-phase plasma protein produced by the liver in response to cytokine 
production during the inflammation response196,197. Our results showed the absence of any 
statistical variation of CRP levels amongst the studied population (0.37 ± 0.48 mg/dL vs 0.09 
± 0.07 mg/dL in patients and controls, respectively). We argue that this observation, may 
also be explained by the patients’ therapy, specifically by the pleiotropic effects of statins, 
which reduces CRP circulating levels195,198. In addition, the anti-inflammatory therapy also 
targets cytokines like IL-1β186.  
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CRP participates in all stages of atherosclerosis development54. Elevation of plasma CRP 
levels occurs due to a systemic response to the vascular inflammation199. A recent study 
showed a positive association between CRP and tHcy plasma levels200. Nevertheless, it still 
remains ascertained if inhibition of inflammation response per se will lead to a decrease in 
vascular events rates194. In fact, in a mouse model with CRP deficiency or reduction, it was 
not observed any reduction of the number/size of atherosclerotic lesions201.  
 Fibrinogen 
We have also evaluated fibrinogen plasma levels since fibrinogen, an acute-phase 
inflammatory reactant, increases during the inflammatory response of the vascular wall202. 
Accordingly, high fibrinogen levels have been associated with an increased CVD risk203. 
Nevertheless, in our study, the levels of fibrinogen were similar in CVD patients and controls 
(3636.43 ± 850.20 mg/L and 3422.50 ± 485.31 mg/L, respectively). Once again, we argue 
that the patients’ medication may explain these results. In fact, either the anti-inflammatory 
therapy (like atorvastatin) or the anti-coagulant medication can decrease the fibrinogen levels 
in the plasma, since fibrinogen is a coagulant factor202,204.  
B.2.3. Evaluation of circulating pro-atherogenic mediators 
Adhesion of circulating leukocytes to the EC is an important step in the inflammatory 
process of atherosclerosis and is mediated by the expression of adhesion molecules in 
EC205. ICAM-1 and VCAM-1 are important adhesion molecules whose interaction with 
leucocytes is required for their firm adhesion to the endothelium34. Membrane-bound forms of 
these adhesion molecules are difficult to measure in vivo, but the soluble forms can be 
detected in the plasma and are used to evaluate the inflammatory response of the damaged 
endothelium and its levels of dysfunction206. Thus, in our study, we measured soluble ICAM-1 
(sICAM-1) and soluble VCAM-1 (sVCAM-1) plasma levels. The results were 544.39 ± 59.50 
ng/mL in controls and 1000.91 ± 272.20 ng/mL in patients for sVCAM-1, and 507.62 ± 57.28 
ng/mL in controls and 687.20 ± 191.49 ng/mL in patients for sICAM-1. As illustrated in Figure 
17, sVCAM-1 plasma levels were significantly higher in the patients group when compared to 
controls, but sICAM-1 plasma levels did not change amongst the studied groups.  
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Figure 17. Evaluation of endothelial dysfunction indicators in the studied population. 
Results correspond to mean ± SD. Significant difference is inferred at **p<0.01 vs control using unpaired 
Student’s T test with Welch’s correction. 
Abbreviations: CVD, cardiovascular disease; sVCAM-1, soluble vascular cell adhesion molecule-1; sICAM-1, 
soluble intercellular adhesion molecule-1. 
 
ICAM-1 is constitutively expressed in the vascular wall and its expression is upregulated 
upon a vascular inflammatory response, namely through NF-κB pathway207. Healthy blood 
vessels do not express VCAM-134,205. In a human study, VCAM-1 levels were found to be 
associated with heavy lymphocyte and macrophages infiltration into the intima205. In another 
interesting study, Baccarelli and colleagues, found a link between hypomethylation of 
repetitive LINE-1 (Long Interspersed Nucleotide Elements) sequence and high VCAM-1 
levels in the blood cells of healthy elderly individuals. Repetitive elements, like LINE-1, had 
been used as a measure of global DNA methylation. The authors hypothesized that these 
results could suggest that this link between hypomethylation and VCAM-1 levels may 
represent an early event in CVD208. Furthermore, higher levels of VCAM-1 were found in the 
human serum of atherosclerotic patients101. Additionally, in a study using mice with VCAM-1 
deficiency also suggested that VCAM-1 has a major role in the early stages of 
atherosclerosis, when compared to ICAM-1209.  
Recently, it was found that a high Met intake was linked to higher levels of ICAM-1 and 
VCAM-1210, and since tHcy levels are higher in patients, that could also influence the levels 
of these adhesion molecules. Nonetheless, an increase of these adhesion molecules is 
enough to increase the binding of leukocytes to EC167 to perpetuate the inflammatory 
response.  
The equilibrium between pro-atherogenic cytokines and anti-atherogenic cytokines is 
crucial to determine the atherosclerosis development. In fact, pro-atherogenic cytokine tumor 
necrosis factor-α (TNF-α) can lead to the upregulation of VCAM-1, increasing the interaction 
between leukocytes and EC in humans. On the other hand T-regulatory (Treg) cells mediate 
the secretion of IL-10, and anti-inflammatory and atheroprotective cytokine, which leads to 
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down-regulation of ICAM-1 and TNF-α expression in EC186. This interaction could explain 
why ICAM-1 levels did not change in our studied population, as inflammatory pathways are 
being modulated by the anti-inflammatory therapy taken by CVD patients, which could have 
decreased ICAM-1 levels. Though, further studies are necessary to confirm this interaction. 
Also CRP levels seem to induce the expression of ICAM-1 and VCAM-1, which are 
inversely correlated with HDL levels in monocytes187,196 and in HUVEC211, maybe also 
influencing the values of these parameters in the studied population. 
B.3. H3K27me3 detection in the PBMC of the population 
Dysregulation of histone methylation can lead to activation or repression of endothelial pro-
inflammatory genes, or of inducible NO synthase genes in a vascular disease scenario82. For 
example, recent work by Dreger and colleagues have shown that, in HUVEC, repression of 
NOS2 (gene encoding the inducible NO synthase) was associated with a high H3K27me3 
content212. As previously stated, EZH2-mediated H3K27me3 mark is responsible for the 
epigenetic suppression of several endothelial pro-atherogenic genes213. As a SAM-
dependent histone methyltransferase, EZH2 activity may be inhibited by excess SAH 
decreasing the H3K27me3 content and promoting atherosclerosis. For this reason, we have 
investigated the levels of H3K27me3 in PBMC of our studied populations. Our results, as 
illustrated in Figure 18 show no significant difference between the H3K27me3 content in 
CVD patients and controls. However, since a significant difference has been found in the 
PBMC methylation status (SAM/SAH ratio) between CVD patients and controls, we were 
expecting to observe at least a slight decrease of H3K27me3 content in the patient 
population. Interestingly, a recent study reported a global H3K27me3 reduction in human 
vessels of late atherosclerotic lesions comparing with vessels with early lesions133.  
Other report demonstrated that relative H3K27me3 levels decreased significantly in 
vessels with atherosclerosis compared to healthy ones. Additionally, the causal role of DNA 
methylation in monocytes and lymphocytes (indicated by the methylation status of LINE-1 
sequence) was evaluated and they concluded that there is no difference in the DNA 
methylation status between atherosclerotic and control vessels101. LINE-1 has been identified 
as a mediator of ischemic heart disease damage208.  
 
We argue that the absence of a significant difference between the H3K27me3 content in 
PBMC of CVD patients and controls may be related with the tissue under study. Actually, the 
histone content in PMBC may not reflect the content in atherosclerotic vascular tissues. 
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Figure 18. H3K27me3 relative levels in the studied population.  
Representative Western blot images upon revelation of H3K27me3 and H3t. (B) H3K27me3 (17 kDa) signal was 
normalized upon H3t (17 kDa) signal. Results correspond to mean ± SD. Significant difference is inferred at 
*p<0.05 vs control using unpaired Student’s T test with Welch’s correction. 
Abbreviations: H3K27me3, trimethylation of histone H3 at lysine 27; H3t, histone H3 total. 
 
B.4. Determination of EZH2 and IL-1β expression 
As previously referred, Hcy may be involved in an altered atherosclerosis-related gene 
expression through epigenetic modifications50 and its deleterious action might be mediated 
by SAH, which inhibits most DNA and histone methyltransferases103. And histone methylation 
and DNA methylation have a constant interplay, as histone methylation facilitates DNA 
methylation, which serves as template for histone modifications101.  
As discussed, H3K27me3 levels were similar in control and CVD patients and this result 
suggests that the intracellular amount of SAH might not be sufficient to inhibit the activity of 
EZH2, the histone methyltransferase responsible for H3K27 trimethylation121. However, we 
thought to investigate if SAH levels were sufficient to inhibit DNMT, thus affecting the 
transcription of two specific genes: EZH2 and IL-1β, the last one encoding a target of EZH2 
activity. 
Figure 19. EZH2 and IL-1β relative expressions in the population. 
Abbreviations: EZH2, Enhancer of zeste homolog 2; IL-1β, interleukin-1β. 
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Both genes’ expression was evaluated by qPCR and our results, illustrated in Figure 19, 
demonstrated that neither EZH2 nor IL-1β levels changed in the studied populations. Since 
EZH2 catalyzes the formation of the H3K27me3 mark121, these data agree with the Western 
blot results, which revealed no alteration in the H3K27me3 content. Although IL-1β plasma 
levels did vary significantly between the studied populations, in what concerns IL-1β levels, 
and as its product is a target of EZH2, its expression is consistent with EZH2 results, since 
its expression did not variate amongst the studied groups as well. 
A study with human endometrial stromal cells demonstrated that loss of EZH2 activity can 
lead to chromatin changes214. In a study with EC, EZH2 depletion inhibited endothelial 
proliferation, an important feature to maintain the normal endothelial quiescent state. The 
same study has shown that EZH2 can respond to uniform high fluid shear stress, which is 
atheroprotective, and that EZH2 inhibition or knockdown result in either increase or decrease 
of gene expression215. This study conflicts somehow with our original hypothesis (Figure 4), 
that suggested that low EZH2 activity, promoted by elevated SAH levels, might be 
responsible for the activation of inflammatory genes, through diminishing H3K27me3 content. 
However one thing to take in consideration is that Maleszewska and colleagues215 studied 
the effect of EZH2 in EC under uniform fluid shear stress, that is, in normal blood flow 
conditions. And since we hypothesized that low EZH2 activity mediates the pathogenic state 
in atherosclerosis, maybe there is a fine line between what are standard levels of EZH2 in 
normal conditions and in the beginning and development of atherosclerosis. EZH2 levels or 
activity diminish so that inhibition of EC proliferation is compromised. Maleszewska and 
colleagues’ work215 does not invalid that EZH2 levels or activity may diminish under 
pathogenic conditions. In fact, our group recently showed that in HCAEC, the loss of EZH2 
led to the activation of the inflammatory pathway NF-κB89, corroborating our working 
hypothesis. 
On the other hand, we performed our studies in human PBMC, so EZH2 might have a 
different behavior than in EC. PBMC were chosen as study model for their key role in 
atherosclerosis-related diseases and because they are easy to obtain. Moreover, monocytes’ 
transcriptome seems to reflect genome alterations from the environment134. Plus, leukocytes 
are recruited to the earliest atherosclerotic lesions216. More importantly, loss-of-function 
mutations and deletions in EZH2 where found in T lymphocytes of acute lymphoblastic 
leukemia individuals217, so it could also be a good model to study EZH2 in CVD scenario. 
Our group previously reported that in HCAEC, the expression of EZH2 and IL-1β was 
significantly increased upon SAH accumulation89. We were expecting to have similar results 
in the present study, since higher circulating levels of tHcy were observed in the patients, 
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leading to SAH accumulation, which could increase the expression of IL-1β. Although the 
expression of IL-1β is consistent with EZH2 expression, we cannot reject that PBMC may 
behave differently upon the toxicological effects of SAH. Our results showed that IL-1β levels 
were lower in CVD patients compared with the controls, and again, possibly influenced by 
the anti-inflammatory therapy prescribed to the patients. 
 
 
V – CONCLUSION 
45 
 
 
V – CONCLUSION   
CVD is the leading cause of death in developed countries. Therefore, it is essential to 
disclose new underlying molecular mechanisms and markers for the pathology since 15 - 20 
% of these subjects develop CVD in the absence of known risk factors. In the present study 
we postulated that SAH-induced hypomethylating stress would suppress EZH2 to contribute 
to a pro-atherogenic endothelial phenotype. Nevertheless, we could not establish a role for 
EZH2 in CVD, since EZH2 mRNA levels in PBMC were similar in CVD patients and controls. 
Furthermore, in the same cells, the content of the epigenetic mark that EZH2 establishes, 
H3K27me3, was also similar in the studied populations. However, we were able to detect the 
presence of a hypomethylating environment in PBMC of subjects with established CVD. 
Further, we demonstrated the ability of excess of SAH to decrease an epigenetic mark in 
human EC. In fact, our in vitro study demonstrated that high levels of intracellular SAH led to 
a decrease in the H3K27me3 content in HUVEC. This observation was important to conclude 
that SAH build-up may have a globally epigenetic impact, namely through the regulation of 
histone methylation. These results were reinforced by the low SAM/SAH ratio (a cellular 
methylation indicator) that we observed in the same cells.  
 
Future studies are needed to clarify the role of EZH2 in the beginning and development of 
atherosclerosis and CVD as well as the influence of hypomethylation in EC homeostasis. We 
propose to clarify the role of EZH2 role in atherosclerosis by quantifying the methylation 
levels in EZH2 promoter in a CVD scenario vs normal one, gauging its active transcriptional 
state. Cancer cells studies demonstrate that EZH2 can suffer loss-of-function or gain-of-
function mutations217. Upcoming EZH2 studies could also include a gene sequencing of 
EZH2 in both control and CVD patients, to determinate gene variations that affect EZH2 
enzymatic activity that could result in alteration of H3K27me3 levels. 
We cannot exclude that, besides EZH2, other mediators of atherosclerosis, such as ox-
LDL-c, deficiencies in the cholesterol efflux, or VSMC proliferation can be important 
interveners, contributing to the development of a pathological state. 
 
We chose to study PBMC because they have been described as a good cellular model to 
study CVD. However, we recognize the potential limitations of peripheral blood cells as a 
source for assessing changes in the endothelium; therefore, future studies should analyze, in 
addition, vascular tissue, as for example, aortic and saphenous vein samples collected from 
patients with CVD during elective invasive procedures.  
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Lastly, upcoming studies should also comprise larger cohorts, with detailed medical history 
from the participants, and most importantly, with no influence of chronic therapy. In fact, our 
present results were clearly influenced by the medication of the CVD patients, which affected 
the circulating levels of most lipids analyzed and the levels of IL-1β, a pro-inflammatory 
cytokine.  
 
There were some limitations to this study. The sample size was relatively small and the 
gender distribution was not exactly the same in CVD and control groups.  
 
Our study suggests that controlling the lipid levels is not be effective on reestablishing the 
homeostasis of a previously injured endothelium, since sVCAM-1 levels, an ED marker, are 
still higher in the CVD patients, indicating that ED was still present. Avoiding lipid deposition 
in the blood vessels might not be sufficient to inhibit the atherosclerotic inflammation 
response. Additionally, modulation of the inflammatory response might not also be sufficient 
to prevent future CVD events, as already stated. Again, more studies need to be done to 
elucidate the complex interaction between inflammatory mediators, circulating lipids, ED 
markers, and other unknown participants in a CVD event. 
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